Histotripsy Ablation in Preclinical Animal Models of Cancer and Spontaneous Tumors in Veterinary Patients: A Review

Alissa Hendricks-Wenger, Lauren Arnold, Jessica M. Gannon, Alex Simon, Neha Singh, Hannah Sheppard, Margaret A. Nagai-Singer, Khan Mohammad Imran, Kiho Lee, Sherrie Clark‐Deener, Christopher R. Byron, Michael Edwards, Martha Larson, John H. Rossmeisl, Sheryl Coutermarsh‐Ott, Kristin Eden, Nikolaos Dervisis, Shawna Klahn, Joanne Tuohy, Irving C. Allen, Eli VlaisavljevichIEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control 2021 · DOI

Abstract

New therapeutic strategies are direly needed in the fight against cancer. Histotripsy is the first completely noninvasive, nonthermal, and nonionizing tumor ablation method, capable of producing consistent and rapid ablations even near critical structures. While small animal models have been critical for providing mechanistic insight, they possess significant limitations in terms of scale and anatomical relevance. To address this "translational gap," a diverse range of large animal models and spontaneous tumor studies in veterinary patients have emerged. These models provide realistic avenues for developing and testing histotripsy devices designed for future human use. This review compares histotripsy ablation across a broad spectrum of preclinical models and spontaneous tumors in veterinary patients.

Introduction: The Problem of Scale and Anatomy

While many cancer therapies show promise in murine studies, they often fail in human trials. For focal ablation technologies like histotripsy, small animal models present three primary hurdles:

  1. Scale: A mouse tumor is often smaller than the ultrasound focal zone itself, failing to simulate the challenges of targeting deep-seated human organs.
  2. Anatomy: Mice lack the complex "acoustic windows"—such as rib cages or gas-filled bowels—that complicate ultrasound delivery in larger bodies.
  3. Biological Complexity: Lab-grown tumors in inbred mice lack the genetic heterogeneity and complex immune environments of naturally occurring human cancers.

Methodology: Scaling the Technology

The transition from benchtop to bedside requires distinct hardware configurations. Small animal systems typically utilize custom 1-MHz transducers designed for high precision at shallow depths (<1.5 cm). In contrast, clinical prototypes for large animals and humans use 500-kHz, multi-element arrays mounted on robotic micropositioners, designed for depths of approximately 7 cm and integrated with clinical-grade real-time ultrasound imaging.

Both systems rely on acoustic cavitation, where microsecond-long, high-pressure ultrasound pulses generate "bubble clouds." These clouds mechanically homogenize target tissue into acellular debris without generating heat, allowing for tissue-selective ablation that can spare critical structures like major blood vessels.

Key Results in Large Animal and Veterinary Models

The research highlights several breakthroughs in moving beyond rodent models:

  • Genetically Engineered Porcine Models: The development of immunocompromised pigs (RAG2/IL2RG deficient) allows for the hosting of human cancer cell lines, creating "human-sized" tumors within a body that mimics human organ structures.
  • Porcine Pancreas Ablation: Researchers reported the first instance of histotripsy used to target the pancreas in a large animal, identifying stomach gas as a primary hurdle for the acoustic window.
  • Comparative Oncology in Canines: Client-owned pet dogs with spontaneous Soft Tissue Sarcoma (STS) and Osteosarcoma (OS) serve as "sentinel" models. Because these dogs share human environments and have intact immune systems, they provide a rigorous test for histotripsy’s ability to stimulate systemic anti-tumor immune responses.
CT imaging of histotripsy targets across various models, including canine osteosarcoma (a), soft tissue sarcomas (b, c), and abdominal targets (d, e).

In canine clinical pilots, histotripsy produced well-defined ablation zones visible on CT as regions of decreased contrast uptake. Histology confirmed extensive cell necrosis and hemorrhage within the targeted volumes, matching planned 3-cm treatment zones.

Limitations and Future Directions

Despite these successes, challenges remain regarding acoustic windows. Gas in the GI tract and the high density of bone can block or distort ultrasound waves. Future work is focused on developing "acoustic nutrients" (specialized diets) to clear bowel gas and improving transcostal delivery methods. Additionally, while CT and MRI can identify ablation zones, improved multi-modal imaging is needed to better distinguish between liquefied tissue and surrounding edema. The next major frontier is quantifying the systemic immune response triggered by the release of tumor antigens during mechanical homogenization.

Summary updated

Abstract

New therapeutic strategies are direly needed in the fight against cancer. Over the last decade, several tumor ablation strategies have emerged as stand-alone or combination therapies. Histotripsy is the first completely noninvasive, nonthermal, and nonionizing tumor ablation method. Histotripsy can produce consistent and rapid ablations, even near critical structures. Additional benefits include real-time image guidance, high precision, and the ability to treat tumors of any predetermined size and shape. Unfortunately, the lack of clinically and physiologically relevant preclinical cancer models is often a significant limitation with all focal tumor ablation strategies. The majority of studies testing histotripsy for cancer treatment have focused on small animal models, which have been critical in moving this field forward and will continue to be essential for providing mechanistic insight. While these small animal models have notable translational value, there are significant limitations in terms of scale and anatomical relevance. To address these limitations, a diverse range of large animal models and spontaneous tumor studies in veterinary patients have emerged to complement existing rodent models. These models and veterinary patients are excellent at providing realistic avenues for developing and testing histotripsy devices and techniques designed for future use in human patients. Here, we provide a review of animal models used in preclinical histotripsy studies and compare histotripsy ablation in these models using a series of original case reports across a broad spectrum of preclinical animal models and spontaneous tumors in veterinary patients.
BibTeX
@article{hendrickswenger2021histotripsy,
  author = {Alissa Hendricks-Wenger and Lauren Arnold and Jessica M. Gannon and Alex Simon and Neha Singh and Hannah Sheppard and Margaret A. Nagai-Singer and Khan Mohammad Imran and Kiho Lee and Sherrie Clark‐Deener and Christopher R. Byron and Michael Edwards and Martha Larson and John H. Rossmeisl and Sheryl Coutermarsh‐Ott and Kristin Eden and Nikolaos Dervisis and Shawna Klahn and Joanne Tuohy and Irving C. Allen and Eli Vlaisavljevich},
  title = {{Histotripsy Ablation in Preclinical Animal Models of Cancer and Spontaneous Tumors in Veterinary Patients: A Review}},
  journal = {IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control},
  year = {2021},
  doi = {10.1109/tuffc.2021.3110083},
}
Figure